Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine Nasal Spray for Acute Anxiety States
NCT07550881Phase 2Recruiting
- Sponsor
- Tongji University
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anxiety disorder comparing Dexmedetomidine Group with Placebo Group (2 arms). Primary endpoint: Proportion of patients with a Clinical Global Impression - Improvement score <= 2 at 15 minutes. Started Apr 2026; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT07550881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550881.